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Sarcoidosis is a granulomatous disorder of unknown etiology, associated with an accumulation of CD4+ T cells
and a TH1 immune response. Since previous studies of HLA associations with sarcoidosis were limited by serologic
or low-resolution molecular identiﬁcation, we performed high-resolution typing for the HLA-DPB1, HLA-DQB1,
HLA-DRB1, and HLA-DRB3 loci and the presence of the DRB4 or DRB5 locus, to deﬁne HLA class II associations
with sarcoidosis. A Case Control Etiologic Study of Sarcoidosis (ACCESS) enrolled biopsy-conﬁrmed cases (736
total) from 10 centers in the United States. Seven hundred six (706) controls were case matched for age, race, sex,
and geographic area. We studied the ﬁrst 474 ACCESS patients and case-matched controls. The HLA-DRB1 alleles
were differentially distributed between cases and controls ( ). The HLA-DRB1*1101 allele was associatedP ! .0001
( ) with sarcoidosis in blacks and whites and had a population attributable risk of 16% in blacks and 9%P ! .01
in whites. HLA-DRB1-F47 was the amino acid residue most associated with sarcoidosis and independently associated
with sarcoidosis in whites. The HLA-DPB1 locus also contributed to susceptibility for sarcoidosis and, in contrast
to chronic beryllium disease, a non–E69-containing allele, HLA-DPB1*0101, conveyed most of the risk. Although
signiﬁcant differences were observed in the distribution of HLA class II alleles between blacks and whites, only
HLA-DRB1*1501 was differentially associated with sarcoidosis ( ). In addition to being susceptibility mark-P ! .003
ers, HLA class II alleles may be markers for different phenotypes of sarcoidosis (DRB1*0401 for eye in blacks and
whites, DRB3 for bone marrow in blacks, and DPB1*0101 for hypercalcemia in whites). These studies conﬁrm a
genetic predisposition for sarcoidosis and present evidence for the allelic variation at the HLA-DRB1 locus as a
major contributor.
Introduction
Sarcoidosis (MIM 181000) is a systemic granulomatous
disease that was originally described over 100 years ago
(Newman et al. 1997). Pulmonary involvement occurs
in about 90% of cases, but any organ system can be
involved. Skin, eye, cardiac, liver and neurologic man-
ifestations are not uncommon. The disorder has been
described in all races and in every continent except Ant-
arctica (Siltzbach et al. 1974). While many cases may
undergo spontaneous regression, one-third of cases may
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be persistent and require therapy. An infectious agent
has been suspected as the cause of this disorder, but no
speciﬁc etiology has been identiﬁed (Newman et al.
1997).
The inﬂammatory response in sarcoidosis has been
characterized by the accumulation of CD4 T cells at
the sites of disease activity (Hunninghake and Crystal
1981). A TH1 type response has been suspected because
of the granulomatous response and has been supported
by the ﬁndings of increased levels of IL-2 and INF-
gamma (Pinkston et al. 1983). The T cells expressed
oligoclonal T cell receptors consistent with a response
to an environmental antigen (Moller 1998). These ﬁnd-
ings strongly supported an excessive inﬂammatory re-
action or hypersensitivity to some innocuous agent. The
utility of corticosteroids and other anti-inﬂammatory
drugs in the treatment of this disorder supported this
idea.
A genetic susceptibility to sarcoidosis has been sup-
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ported by studies demonstrating familial clustering (Ry-
bicki et al. 2001b). First-degree relatives have a higher
prevalence of disease, and familial clustering has been
observed in different populations but most noticeably
in African Americans (Rybicki et al. 2001a). Polymor-
phisms of a number of candidate genes have been as-
sociated with sarcoidosis (Arbustini et al. 1996; Ishihara
et al. 1996; Rybicki et al. 1999; Pandey and Frederick
2002; Planck et al. 2002; Zorzetto et al. 2002). Sero-
logic and molecular analyses of HLA molecules have
also been investigated in sarcoidosis. Unfortunately, be-
cause of the limitations of study design and technique
of identiﬁcation ofHLAmolecules (serological and low-
resolution molecular typing), a consensus of the im-
portance of HLA molecules in sarcoidosis has not been
achieved (reviewed by Martinetti et al. [2002]).
HLA genes have long been recognized for their im-
portance in transplantation, but only in the last decade
has their role in the immune response been elucidated
(Klein and Sato 2000). The HLA region is located on
the short arm of chromosome 6 and is one of the most
gene-dense regions of the genome (MHC Sequencing
Consortium 1999). Within this region, the highly poly-
morphicHLA class I and class II genes are located.HLA
class II molecules consist of heterodimers of a and b
chains which contain a groove that anchors a 10–25–
amino acid peptide. However, this groove is occupied
by the invariant chain, which prevents it from binding
peptides until this HLA molecule is transferred to the
endosomal-lysosomal compartment. In this compart-
ment, 10–25–amino acid peptides of extracellular origin
bind to the groove of the class II molecule. The amino
acids that line this groove determine the afﬁnity of the
groove for these peptides. This bimolecular complex is
then expressed on the cell surface where CD4 T cells
can recognize it. The polymorphism of the HLA class
I and II molecules is predominately accounted for by
differences in the amino acids that line the peptide-bind-
ing groove. This groove can be grouped into speciﬁc
areas or pockets that interact with the amino acids of
the peptide. Certain amino acid substitutions are critical
for determining peptide afﬁnity, and alleles can be
grouped according to these amino acid substitutions.
Thus, HLA gene products play a direct role in the im-
mune response, and disease associations with the HLA
genes have been associated not only with speciﬁc alleles
but also with speciﬁc amino acids that deﬁne a speciﬁc
class of alleles.
Previous studies ofHLA associations with sarcoidosis
were limited by including patients without histological
conﬁrmation of disease and by methods that relied on
the inexact serologic or low-resolution molecular iden-
tiﬁcation of the HLA molecules (Pasturenzi et al. 1993;
Ishihara et al. 1994; Martinetti et al. 1995). Since the
ability to develop a CD4 T cell response in sarcoidosis
probably depends on speciﬁc immunogenic peptides
binding to HLA class II molecules, the aim of this study
was to perform high-resolution molecular HLA class II
typing in cases with histologically conﬁrmed sarcoidosis
and well-matched controls to determine whether sus-
ceptibility to sarcoidosis could be associated with spe-
ciﬁcHLA class II alleles or groups ofHLA class II alleles
with common amino acid residues involved in peptide
binding.
Materials and Methods
Study Design
Blood specimens were collected prospectively frompa-
tients and matched controls who were entered into a
case-control etiologic study of sarcoidosis (ACCESS)
(Group 1999). Ten U.S. academic medical centers, one
coordinating center, a DNA core laboratory, and a des-
ignated HLA laboratory participated in the design, en-
rollment, data entry, and analysis. The National Heart,
Lung, and Blood Institute (NHLBI), which appointed a
Data and Safety Monitoring Board and study chair, pro-
vided oversight and funding. Between November 1996
and June 1999, 736 cases with 706 matched controls
were entered into the study. The ﬁrst 474 cases and
matched controls make up the study sample for which
HLA studies were performed. All cases and controls
completed informed consent forms, in accordance with
a protocol approved by the institutional review boards
of all participating centers.
Cases
Cases of sarcoidosis were recruited prospectively
within geographic regions surrounding the 10 partici-
pating clinical centers between 1996 and 1999 (Group
1999). Cases met the following inclusion criteria: (1) ﬁrst
tissue conﬁrmation of noncaseating granulomas on bi-
opsy within 6 mo of enrollment, (2) clinical signs or
symptoms consistent with sarcoidosis, and (3) age 18
years. Speciﬁc phenotypes of sarcoidosis were deter-
mined with an instrument developed by the ACCESS
group (Judson et al. 1999). Excluded were individuals
with fungal disease, with active tuberculosis, or who
were taking antituberculosis therapy. Patients with a his-
tory of beryllium exposure were excluded, unless they
had a negative blood beryllium lymphocyte proliferation
test. Pathology slides were reviewed by a study pathol-
ogist at each clinical center, and the medical records,
chest radiographs, and study tests were reviewed by the
principal investigator at each clinical center. An inter-
viewer-administered questionnaire was given to each
participant. The clinical characteristics of the study pa-
tients were reported elsewhere (Baughman et al. 2001).
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Controls
Controls were recruited by random digit dialing
(RDD) methods (Waksberg 1978; Group 1999; Baum-
gartner et al. 2000) from within the same geographic
region as cases. Controls were matched to cases on the
basis of age (within 5 years), gender, and self-reported
race and ethnicity. Controls were excluded if they re-
ported a history of sarcoidosis or medical conditions that
made the determination of sarcoidosis uncertain (e.g.,
granulomatous hepatitis, idiopathic uveitis).
DNA Preparation
Heparinized blood was collected from each case and
control at the time of the interview and was sent by
overnight courier to the DNA core laboratory for pu-
riﬁcation of the DNA.High–molecular-weight DNAwas
isolated from anticoagulated blood by detergent lysis
and organic extraction (Zoghbi et al. 1989). Puriﬁed
DNA samples were diluted to a standard concentration
in 10 mM Tris, 5 mM EDTA buffer, and were frozen at
70C until used. DNA integrity and concentration
were monitored using agarose gel electrophoresis and
ethidium bromide staining.
HLA Identiﬁcation
Masked samples of DNA were sent to theHLA typing
laboratory for analysis of HLA class II alleles. Low- to
intermediate-resolution typing was performed for
DRB1, DRB3, DQB1, and DPB1 by use of the SSOP
method and the NMDP set of probes by Orchid Diag-
nostics (formerly “Lifecodes”).
PCR with sequence-speciﬁc primers.—PCR with se-
quence-speciﬁc primers, performed using ARMS tech-
nology, was utilized for high-resolution typing of HLA-
DRB1, HLA-DRB3, and HLA-DPB1. Depending on
the low-resolution results, appropriate kits (Olerup SSP,
by Genovision) were chosen for subtyping of DRB1,
DRB3, andDPB1 loci (high-resolution typing). The am-
pliﬁcation product was then electrophoresed on a 1.5%
agarose gel. The pattern of PCR products and product
size was analyzed so that speciﬁc alleles could be iden-
tiﬁed. The DR4- and DR5- loci were identiﬁed only as
being present or absent, and no allelic assignments were
made.
Quality Control
Repeat typing of HLA-DRB1, HLA-DQB1, and
HLA-DPB1 alleles was performed on 5% of the study
sample. Unblinding of the quality-control samples was
performed only after both samples had been completely
analyzed.
Statistical Evaluation
ACCESS data were analyzed using matched case-con-
trol analysis methods. Analyses of categorical variables
used McNemar’s test (McNemar 1947). Matched logis-
tic regression analyses were performed using the meth-
ods described by Breslow and Day (1980). The PHREG
procedure in SAS was used to analyze these data.
A large number of statistical tests were performed in
the analysis of these data. Two analytical techniques
were used to address the potential for spurious associ-
ations. Our ﬁrst approach to reduction of the number
of spurious associations involved a global x2 test, which
was performed within each of the DRB1, DQB1, and
DPB1 allele groups. Each test addressed the null hy-
pothesis that all of the odds ratios (ORs) for the alleles
in the grouping were equal to 1 versus the alternative
that at least one OR was different from 1. Alleles and
epitopes that can be tracked back to a signiﬁcant allele
grouping are more likely not to be spurious associations,
since a single test has determined that it is more likely
that the grouping is related to sarcoidosis. Alleles and
amino acid epitopes that were identiﬁed as being related
to case-control status but were not members of a sig-
niﬁcant allele grouping are downplayed in this article.
In our second approach, a stepwise logistic regression
was used to obtain the most parsimonious model that
relates alleles and amino acid epitopes to sarcoidosis.
Some of the variables mentioned above were present in
very low frequencies. The inclusion of these variables
resulted in singular information matrices that destabi-
lized the model that was being generated. The variables
resulting in singularities that destabilized the model were
excluded from the logistic regression models but were
part of the univariate analyses. In our logistic regression
analyses, P values 1.05 were deemed to be statistically
signiﬁcant, and P values between .05 and .1 were deemed
to indicate trends.
To assess whether the inﬂuence of alleles and amino
acid epitopes was the same across different age, race, or
sex groups, we performed interaction analyses with gen-
der, race, or age serving as an effect modiﬁer. The effect
modiﬁer was introduced as an interaction in thematched
logistic regression model. The null hypothesis associated
with this test was that the OR relating the impact of the
allele/epitope was the same in the two groups (e.g., white
vs. black) versus the alternative that the ORs were dif-
ferent. In model terms, we tested the null hypothesis that
the interaction coefﬁcient was equal to 0 versus the al-
ternative that the coefﬁcient was different from 0. A P
value of .05 was used to determine whether the inter-
action term was statistically different from 0. Since not
all individuals expressed a DRB4 or DRB5 allele, the
association of the presence of any of these alleles with
sarcoidosis was determined by x2 analysis.
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To address whether alleles and amino acid epitopes
were associated with different clinical phenotypic ex-
pressions of sarcoidosis, a x2 test was performed to test
whether the clinical phenotype was equally prevalent in
sarcoidosis patients who had the allele/amino acid epi-
tope compared to those who did not have the allele/
amino acid epitope. The signiﬁcance level for the P value
was set at .05. Statistical tests and logistic regression
models were performed for the ACCESS group as a
whole and within each age, race, and gender group.
To determine the proportion of the excess disease rate
that might be attributable to a speciﬁc allele, the pop-
ulation attributable risk (PAR%) (Schildkraut 1998)was
calculated from the following formula:
P (RR 1)ePAR%p # 100 ,
P (RR 1) 1e
where Pe is the prevalence of the allele in the general
population, and RR is the relative risk.
Although controls represented a population age-/race-
/sex-matched to the cases, we approximated the prev-
alence of an allele in the general population by using
the prevalence of the allele in the control population and
the RR by using the OR (rare disease assumption).
Results
Overview of the Study Population
TheHLA typing laboratory received 1,016 DNA sam-
ples. All samples, except for one, were successfully typed.
The one sample that could not be typed was contami-
nated. Final results were tabulated on 474matched cases
and controls (948 total samples). In addition, the pres-
ence and absence of a DR3, DR4, or DR5 were also
determined. There were 52 quality-control samples
(5.5%). The remaining 16 samples were from cases and
their matched controls and, on administrative review,
were withdrawn from the study, either because the cases
did not meet study criteria for sarcoidosis or because
the samples were from cases without a matched control.
Among the 948 samples, there were 53 different HLA-
DRB1 alleles, 4 different DRB3 alleles, 19 different
DQB1 alleles, and 41 different DPB1 alleles identiﬁed.
The demographics of this subpopulation of the AC-
CESS study sample for which HLA typing was per-
formed were similar to those of the population as a
whole. There were 311 (66%) that were female pairs in
the HLA study compared with 64% female pairs for the
ACCESS study sample of 706 pairs. For the HLA study,
there were 268 (56%) pairs that self reported as white,
193 (41%) that self reported as black, and 13 (3%) that
were grouped together as “other.” This is similar to the
entire study sample, in which 53% were white, 44%
black, and 3% other. Finally, 206 (44%) of the cases
were !40 years of age in the HLA study compared to
45% !40 years of age in the entire study sample.
Quality control of the HLA typing was performed by
performing duplicate analyses on 52 masked samples.
For each sample, the DRB1, DQB1, and DPB1 alleles
were identiﬁed. Thus, the repeatable typing of 312 alleles
was utilized to assess quality control. Only six alleles
(2%) were not typed similarly. This satisﬁes the re-
quirements set by ASHI (American Society for Histo-
compatibility and Immunogenetics) for HLA typing
laboratories.
Analysis of the HLA-DPB1, HLA-DQB1, and HLA-
DRB1 Alleles in the Study Population
To determine whether there were different allelic dis-
tributions in sarcoidosis patients and their matched
controls, a global test was performed for each allele
group of the 53 DRB1 alleles, the 19 DQB1 alleles, or
the 41 DPB1 alleles detected. Allelic frequencies are
given in tables 1, 2, and 3. The distributions of the
HLA-DRB1 alleles were signiﬁcantly different between
sarcoidosis patients and their matched controls (P !
), whereas the distributions of the alleles for.0001
HLA-DQB1 and HLA-DPB1 were not signiﬁcantly
different ( and for HLA-DQB1 andPp .40 Pp .27
HLA-DPB1, respectively).
To determine which of the HLA-DRB1 alleles ac-
counted for the differences between cases and their
matched controls, univariate analyses were performed.
Seven HLA-DRB1 alleles were signiﬁcant at (ta-P ! .05
ble 4). Three alleles were identiﬁed as risk factors for
sarcoidosis (HLA-DRB1*1101, HLA-DRB1*1501, and
HLA-DRB1*1201), and four alleles were identiﬁed as
protective for the development of sarcoidosis (HLA-
DRB1*0401, HLA-DRB1*0404, HLA-DRB1*0407,
and HLA-DRB1*1503).
Analysis of the DRB3, DRB4, and DRB5 Loci in the
Study Population
The presence of the DRB3 locus was identiﬁed as a
signiﬁcant risk factor for sarcoidosis ( ; ORP ! .006
1.54), while the presence of the DRB4 locus was sig-
niﬁcantly associated with a protective effect ( ;P ! .007
OR 0.69). The presence of the DRB5 locus was not
associated with sarcoidosis ( ; OR 1.22). SincePp .193
the presence of the DRB3 locus was associated with
sarcoidosis, high-resolution typing of the DRB3 locus
was performed. Four alleles were detected, DRB3*0101,
DRB3*0201, DRB3*0202, and DRB3*0301. Only the
presence of DRB3*0101 was identiﬁed as a risk factor
for sarcoidosis with an OR of 1.34 ( ). ThisPp .044
allele was present in 33% of cases and 27% of controls.
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Table 1
HLA-DRB1 Allele Frequency by Case and Control
DRB1
ALLELE
FREQUENCY IN
Entire Cohort Whites Blacks
Cases Controls Cases Controls Cases Controls
0101 .039 .0527 .0560 .0728 .0181 .0233
0102 .0222 .0253 .0168 .0187 .0311 .0363
0103 .0011 .0042 .0019 .0056 … .0026
0301 .1023 .1002 .1381 .1231 .0492 .0674
0302 .0401 .0264 … … .0959 .0622
0303 .0011 .0011 … .0019 .0026 …
0305 .0021 .0011 .0019 .0019 .0026 …
0306 … .0011 … .0019 … …
0401 .0390 .0675 .0616 .1101 .0104 .0130
0402 .0222 .0084 .0392 .0131 … .0026
0403 .0074 .0074 .0112 .0075 .0026 .0026
0404 .0137 .0285 .0205 .0429 .0026 .0104
0405 .0084 .0074 .0056 .0019 .0078 .0130
0407 .0021 .0116 .0037 .0168 … .0052
0408 .0042 .0042 … … … …
0411 … .0021 .0075 .0075 … .0026
0701 .0897 .1086 .0951 .1213 .0881 .0959
0801 .0084 .0137 .0131 .0243 … …
0802 … .0042 … … … .0026
0803 … .0032 … .0037 … …
0804 .0243 .0169 … … .0596 .0415
0806 .0021 .0032 … .0019 .0052 .0052
0901 .0137 .0200 .0131 .0131 .0130 .0311
1001 .0158 .0105 .0093 .0056 .0259 .0155
1101 .1150 .0686 .0840 .0466 .1632 .0984
1102 .0084 .0148 … .0019 .0181 .0337
1103 .0032 .0053 .0037 .0075 .0026 .0026
1104 .0179 .0274 .0280 .0392 .0052 .0078
1110 … .0011 … … … .0026
1114 .0011 … … … .0026 …
1119 … .0011 … … … .0026
1201 .0411 .0222 .0187 .0112 .0751 .0363
1202 .0021 .0032 … … .0052 .0052
1301 .0633 .0665 .0578 .0597 .0699 .0777
1302 .0464 .0496 .0373 .0410 .0596 .0648
1303 .0190 .0148 .0093 .0112 .0285 .0207
1304 .0042 .0084 … .0019 .0104 .0181
1305 .0011 .0021 .0019 .0037 … …
1306 … .0011 … … … .0026
1310 .0011 .0011 … .0019 .0026 …
1315 .0011 … .0019 … … …
1316 .0042 .0063 .0037 .0093 .0052 .0026
1401 .0390 .0232 .0448 .0243 .0259 .0207
1404 .0011 .0042 … .0019 … .0052
1407 .0021 … … … .0052 …
1408 .0011 … .0019 … … …
1421 .0011 … .0019 … … …
1501 .1160 .0770 .1940 .1119 .0104 .0311
1502 .0074 .0053 .0093 .0093 .0026 …
1503 .0338 .0506 … .0019 .0803 .1218
1601 .0053 .0116 .0075 .0187 … .0026
1602 .0053 .0042 … … .0130 .0104
1607 … .0011 … .0019 … …
Analysis of Amino Acid Residues of the HLA Class II
Molecules in the Study Population
Thirty-three (33) HLA-DPB1 residues, 51 HLA-
DQB1 residues, and 60 HLA-DRB1 residues were
tested for their involvement as risk factors for the de-
velopment of sarcoidosis. By univariate analyses (table
5), 12 residues were associated with either cases or con-
trols at the level, and 13 had trends indicatingP  .05
a possible association ( )..05 ! P ! .1
Independent Determinants for the Risk/Protection of
Sarcoidosis in the Study Population
To determine multivariate independence of HLA al-
leles and amino acid residues with sarcoidosis, a forward
logistic regression analysis was performed using all al-
leles and residues that were signiﬁcant at least at the 0.1
alpha level. Six alleles and two amino acid residues were
multivariately associated with cases or controls (table
6). Five DRB1 alleles (DRB1*1101, DRB1*0402,
DRB1*1201, DRB1*1501, and DRB1*1401), one
DRB3 allele (DRB3*0101), and one DPB1 amino acid
residue (DPB1-V76) were identiﬁed as risk factors for
sarcoidosis, whereas only the DRB1 amino acid residue
(DRB1-H13) was identiﬁed as protective for sarcoidosis.
The Inﬂuences of Sex and of Age at Diagnosis on the
Relationship Between HLA Alleles and the
Development of Sarcoidosis
Because prior studies had suggested that there was an
interaction between sex and age at diagnosis of sarcoid-
osis, we performed analyses to determine whether there
were signiﬁcant interactions of these variables with the
HLA alleles and sarcoidosis. Only four alleles were iden-
tiﬁed as having possible interactions ( ) with sexP ! .10
or age at diagnosis. Interestingly, two of these alleles
were also independently associated with sarcoidosis.
HLA-DRB1*1101, which was a risk factor for sarcoid-
osis in the study population, had a higher OR in males
than in females (OR 3.6 for males and 1.51 for females;
). HLA-DRB1*0401, which was identiﬁed asPp .053
a protective factor, had a lower OR in males than in
females (OR 0.25 for males and 0.69 for females;
). DQB1*0603 was not originally identiﬁed asPp .078
associated with sarcoidosis in the study population
( ; OR 0.98). The interaction analysis identi-Pp 1.000
ﬁed DQB1*0603 as a risk factor for females and a pro-
tective factor for males (OR 1.32 for females and 0.50
for males; ). Similarly, HLA-DRB1*1302 wasPp .062
not associated with sarcoidosis in the study population
( ; OR 1.00) but was identiﬁed as a risk factorPp 1.000
for early-onset sarcoidosis and a protective factor for
late-onset sarcoidosis (OR 1.65 for sarcoidosis at age
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Table 2
HLA-DPB1 Allele Frequency by Case and Control
DPB1
ALLELE
FREQUENCY IN
Entire Cohort Whites Blacks
Cases Controls Cases Controls Cases Controls
0101 .1804 .1521 .0690 .0616 .3394 .2727
0201 .1023 .1309 .1045 .1306 .0933 .1299
0202 .0032 .0042 .0019 .0075 .0052 …
0301 .0897 .0739 .1063 .0896 .0699 .0571
0401 .2795 .2883 .4310 .4254 .0674 .1039
0402 .1065 .1193 .0970 .1213 .1166 .1117
0501 .0137 .0116 .0224 .0149 … .0052
0601 .0063 .0127 .0112 .0205 … .0026
0801 .0011 … .0019 … … …
0901 .0063 .0042 .0093 .0037 .0026 .0052
1001 .0105 .0084 .0168 .0131 … .0026
1101 .0306 .0359 .0205 .0354 .0466 .0390
1301 .0243 .038 .0112 .0243 .0415 .0597
1401 .0137 .0084 .0205 .0056 .0026 .0026
1501 .0063 .0084 .0093 .0056 .0026 .0130
1601 .0053 .0053 .0093 .0075 … .0026
1701 .0380 .0348 .0168 .0093 .0674 .0701
1801 .0295 .0296 … … .0725 .0727
1901 .0053 .0063 .0075 .0075 .0026 .0052
2001 .0011 .0011 .0019 .0019 … …
2301 .0084 .0021 .0149 .0037 … …
2501 .0011 … .0019 … … …
2601 .0011 … … … .0026 …
2701 .0095 .0084 … … .0233 .0208
2901 .0021 .0011 .0037 … … .0026
3001 .0032 .0011 … … .0078 .0026
3201 .0011 … .0019 … … …
3401 .0011 … … … .0026 …
3601 … .0011 … .0019 … …
3901 .0042 .0042 … .0037 .0104 .0052
4001 .0063 .0032 … … .0155 .0078
4101 .0011 … .0019 … … …
4901 .0011 .0011 … … .0026 .0026
5001 .0011 … .0019 … … …
5101 … .0011 … .0019 … …
5201 .0011 .0011 .0019 .0019 … …
5501 .0011 .0011 .0019 … … .0026
6501 … .0011 … .0019 … …
7201 .0011 … .0019 … … …
7601 .0011 … … … .0026 …
8001 .0011 … … … .0026 …
Table 3
HLA-DQB1 Allele Frequency by Case and Control
DQB1
ALLELE
FREQUENCY IN
Entire Cohort Whites Blacks
Cases Controls Cases Controls Cases Controls
0201 .1055 .1023 .1362 .1250 .0596 .0699
0202 .1023 .1150 .0877 .1007 .1269 .1399
0203 .0032 .0011 … … .0078 .0026
0301 .1751 .1888 .1828 .1978 .1658 .1736
0302 .0622 .0833 .0951 .1082 .0181 .0440
0303 .0200 .0253 .0224 .0354 .0155 .0130
0304 .0042 .0032 .0075 .0056 … …
0305 .0053 .0011 .0093 .0019 … …
0401 .0032 .0011 .0037 .0019 … …
0402 .0454 .0454 .0093 .0261 .0933 .0674
0501 .1255 .1297 .0858 .1026 .1865 .1684
0502 .0327 .0179 .0224 .0205 .0466 .0155
0503 .0422 .0264 .0466 .0261 .0285 .0207
0601 .0074 .0053 .0112 .0093 .0026 …
0602 .1688 .1519 .1754 .1194 .1632 .2021
0603 .0538 .0549 .0672 .0765 .0337 .0259
0604 .0253 .0285 .0317 .0336 .0155 .0233
0608 .0011 .0021 … … .0026 .0052
0609 .0169 .0169 .0056 .0093 .0337 .0285
!40 years vs. OR 0.56 for sarcoidosis at age 40 years;
for interaction).Pp .028
Analyses Based Within Race Groups
Using analytical methods analogous to those used for
the entire study population, we investigated the inter-
relationships of race with HLA alleles and amino acid
residues in sarcoidosis. The global test identiﬁed that at
least one of the HLA-DRB1 alleles was associated with
sarcoidosis in whites and blacks ( for whites andP ! .001
for blacks). There were no global effects iden-Pp .0084
tiﬁed for the HLA-DQB1 loci in either whites or blacks
( for whites and for blacks). However,Pp .31 Pp .17
the global test identiﬁed that at least one of the HLA-
DPB1 alleles was associated with sarcoidosis in blacks
( ).Pp .03
Table 7 shows the results of univariate analyses for
whites and blacks (tables 1, 2, and 3 give the allele fre-
quencies). We identiﬁed three alleles that were risk fac-
tors for blacks with sarcoidosis (HLA-DRB1*1101,
HLA-DRB1*1201, and HLA-DPB1*0101) and one
allele that was protective (HLA-DRB1*1503). Three
alleles were identiﬁed as risk factors for sarcoidosis
in whites (HLA-DRB1*1101, HLA-DRB1*0402, and
HLA-DRB1*1501), and one allele was identiﬁed as a
protective factor (HLA-DRB1*0401). Only a single
HLA-DPB1 allele (HLA-DPB1*0101) was identiﬁed in
blacks as a risk factor for sarcoidosis.
Population attributable risk estimates in blacks were
as follows: for HLA-DRB1*1101, 16%; HLA-DRB1*
1201, 11%; and HLA-DPB1*0101 was 24%. For
whites, the population attributable risk estimates were
as follows: for HLA-DRB1*1101, 9%; for DRB1*
0402, 5%; and forDRB1*1501, 18%. Thus, if the prev-
alence of these alleles in our black and white control
populations is similar to the prevalence of these alleles
in the black and white populations of the United States,
these alleles represent substantial risk factors for the de-
velopment of sarcoidosis.
Interaction tests were performed to determine if alleles
were differentially associated with sarcoidosis in whites
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Table 4
HLA-DRB1 Alleles Associated with Sarcoidosis or Controls with Univariate P ! .05
HLA-DRB1 Allele
Frequency
in Cases
(%)
Frequency
in Controls
(%) P OR (95% CI)
Associated with Sarcoidosis:
1101 22 13 !.001 1.98 (1.37–2.90)
1501 22 14 .003 1.70 (1.18–2.46)
1201 8 4 .015 2.13 (1.14–4.12)
Associated with Controls:
0401 8 13 .003 .48 (.28–.80)
0407 0 2 .022 .18 (.02–.83)
0404 3 6 .034 .46 (.21–.95)
1503 6 10 .048 .57 (.32–1.00)
Table 5
HLA-DRB1-, DQB1-, and DPB1- Amino Acid Residues
Associated with Sarcoidosis
Amino Acid Residue P OR (95% CI)
Associated with Sarcoidosis:
DRB1-F47 !.00 1.63 (1.18–2.27)
DPB1-V76 !.00 1.49 (1.13–1.98)
DRB1-S13 .02 1.43 (1.07–1.92)
DRB1-E58 .03 1.41 (1.03–1.95)
DQB1-A86 .03 1.35 (1.02–1.78)
DQB1-E84 .05 1.33 (1.01–1.77)
DRB1-Y10 .06 1.38 (.99–1.94)
DRB1-S11 .06 1.38 (.99–1.94)
DQB1-R55 .06 1.32 (.99–1.78)
DQB1-G89 .06 1.31 (.99–1.74)
DQB1-Q53 .06 1.31 (.99–1.74)
DQB1-G70 .06 1.30 (.99–1.72)
DQB1-S57 .07 1.87 (.96–3.76)
DPB1-D84 .08 1.30 (.97–1.75)
DRB1-A74 .09 1.45 (.95–2.23)
DRB1-H32 .09 1.27 (.97–1.66)
Associated with Controls:
DRB1-H13 !.00 .59 (.41–.83)
DRB1-Q70R71 .01 .64 (.47–.88)
DRB1-Q10 .01 .66 (.49–.89)
DRB1-V11 .01 .67 (.48–.93)
DRB1-K12 .02 .69 (.51–.94)
DRB1-I31 .03 .68 (.47–.97)
DPB1-E69 .06 .77 (.59–1.01)
DPB1-I65 .06 .36 (.10–1.05)
DRB1-F13 .09 .75 (.53–1.04)
and blacks. Only one allele, HLA-DRB1*1501, had a
signiﬁcant interaction between blacks and whites (OR
0.36 for blacks and 2.08 for whites; forPp .003
interaction).
By univariate analysis, 22 amino acid residues in
blacks and 16 amino acid residues in whites were as-
sociated with sarcoidosis ( ), and 11 amino acidP ! .05
residues in blacks and 13 amino acid residues in whites
were identiﬁed as having interesting trends (.05 ! P !
[data not shown])..10
The presence of the DRB3 locus was identiﬁed as a
risk factor for blacks but not for whites (for blacks, OR
2.11, ; for whites, OR 1.30, ). ThePp .010 Pp .191
presence of the DRB4 locus was identiﬁed with protec-
tion from sarcoidosis for blacks but not for whites (for
blacks, OR 0.61, ; for whites, OR 0.72,Pp .042 Pp
). Since the test for interaction between blacks and.071
whites for the presence of the DRB3 or DRB4 locus was
not signiﬁcant, these differences only indicate trends
rather than signiﬁcant ﬁndings. The interaction test iden-
tiﬁed the presence of the DRB5 locus as being differ-
entially associated with sarcoidosis between blacks and
whites, despite the lack of association with the entire
study population (OR 0.57 for blacks and 1.23 for
whites; for interaction). High-resolution typ-Pp .002
ing identiﬁed three DRB3 alleles in blacks (DRB3*0101,
DRB3*0202, and DRB3*0301). Whereas none of these
alleles was signiﬁcantly associated with sarcoidosis, by
univariate analyses, DRB3*0303 was trending as a risk
factor for sarcoidosis (OR 1.64; ).Pp .064
To determine multivariate independence of alleles and
amino acid residues in whites and blacks with sarcoid-
osis, the amino acid residues and the alleles of HLA-
DRB1, HLA-DRB3, HLA-DPB1, and HLA-DQB1
were entered into a forward logistic regression (table 8).
In blacks, four alleles (DPB1*0101, DRB1*1201,
DRB1*1101, and DQB1*0502) were identiﬁed as risk
factors for sarcoidosis, and two amino acid residues
(DRB1-Y26 and DRB1-Q10) were identiﬁed as protective
factors ( ). In whites, four alleles (DRB1*1101,P ! .05
DRB1*1501, DRB1*1401, andDRB1*0402) and three
amino acid residues (DPB1-F35, DPB1-H9, and DRB1-
F47) were identiﬁed as risk factors for sarcoidosis, and
two amino acid residues (DPB1-I65 and DRB1-F26) and
one allele (DQB1*0602) were identiﬁed as protective
factors ( ).P ! .05
Sarcoidosis Phenotypes Associated with HLA Alleles
The alleles associated with sarcoidosis were evaluated
to determine whether they correlated with different phe-
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Table 6
Forward Logistic Regression Analysis of the Association
of HLA-DRB1, HLA-DRB3, HLA-DQB1, and HLA-DPB1
Alleles and Amino Acid Residues and Sarcoidosis
Allele or
Amino Acid Residue OR (95% CI) P
Associated with Sarcoidosis:
DRB1*1101 2.68 (1.78–4.03) !.001
DRB1*0402 4.59 (1.76–12.0) .002
DRB1*1201 2.62 (1.38–4.95) .003
DRB1*1501 1.84 (1.22–2.77) .004
DRB3*0101 1.60 (1.16–2.20) .004
DPB1-V76 1.56 (1.14–2.12) .005
DRB1*1401 2.29 (1.21–4.34) .011
Associated with Controls:
DRB1-H13 .32 (.12–.87) .026
notypes of sarcoidosis at presentation. On the basis of
the ACCESS questionnaire (Judson et al. 1999), involve-
ment at presentation was assessed in 16 different systems
as either deﬁnite, probable, possible, or not involved. If
a subject had deﬁnite or probable involvement with sar-
coidosis for a particular system, this system was consid-
ered involved with sarcoidosis for this analysis. In three
organ systems (bone and joint, muscle, and renal), in-
volvement was detected in !2% of cases. Ten different
alleles were tested for their association with speciﬁc sys-
tems in all patients and in blacks and whites. Univari-
ate ( ) associations are shown in table 9. TheP ! .05
most signiﬁcant ﬁnding was the relationship between
DRB1*0401 and eye involvement ( ; OR 3.49)P ! .0008
in the study population. Although only 2% of blacks
had a DRB1*0401 allele, a similar OR was present in
both blacks and whites. The association ofDRB1*1503
with extrathoracic lymph node and neurological involve-
ment in the study population was confounded, since
DRB1*1503 was only present in blacks and extrathor-
acic lymph node and neurological involvement were also
associated with blacks. When these associations were
examined in just the black population, the association
was less striking, with a decreased OR and a decreased
level of signiﬁcance. The presence of the DRB3 locus
was strongly associated with bone marrow involvement
in blacks (OR 6.71; ), but, because of the rarityPp .004
of bone marrow involvement in whites (∼0.4%), no as-
sociation could be demonstrated. DPB1*0101 was not
associated with any particular organ involvement in
blacks but was strongly associated with hypercalcemia
in whites ( ; OR 4.28). The other signiﬁcant as-P ! .005
sociation ( ) present in this analysis was the pres-P ! .01
ence of DRB1*0401 and parotid and salivary gland in-
volvement in blacks ( ; OR 78.0).P ! .001
Discussion
Although prior studies have suggested that there was an
association between HLA alleles and sarcoidosis, sar-
coidosis has not been generally recognized as a disease
with signiﬁcant HLA mediation in its development
(Hansen et al. 1993; Klein and Sato 2000). A genetic
predisposition to sarcoidosis has been suspected (re-
viewed by Rybicki et al. [2001a]), and a recent study of
a genomewide search for predisposing genes in sarcoid-
osis suggested that not only was there a locus hetero-
geneity of susceptibility but the most prominent peak
was noted in the HLA region (Schurmann et al. 2001).
Our study extends this observation by showing that the
DRB1 locus appears to be an important class II locus
associated with susceptibility to sarcoidosis.
In this, the largest case-control study of high-reso-
lution identiﬁcation of HLA polymorphisms in sarcoid-
osis, our global test to evaluate allelic heterogeneity
clearly showed a very strong association between sar-
coidosis and the HLA class II DRB1 locus ( )P ! .0001
and conﬁrmed the initial observations of a DR associ-
ation with sarcoidosis (Krause and Goebel 1987; Ku-
nikane et al. 1987). Using logistic regression, we dem-
onstrated that both speciﬁc alleles and amino acid
residues appeared to independently confer risk for sar-
coidosis. This could mean that single and multiple
amino acid changes might be instrumental in deﬁning
the population of individuals who are at risk for de-
veloping sarcoidosis. In addition, the logistic regression
identiﬁed two additional HLA-DRB1 alleles not iden-
tiﬁed by univariable analysis and an amino acid resi-
due on HLA-DPB1 that appeared to be associated
with sarcoidosis. Although univariate associations were
noted for DRB3, DRB4, and DRB5 loci, only the
DRB3*0101 allele was associated with sarcoidosis
when considered with the other candidate alleles and
amino acid residues in the logistic regression. This sug-
gests that the other univariate associations identiﬁed in
this analysis could be due to linkage disequilibrium or
multiple comparisons
Because HLA class II allele distributions differ among
different populations, we also investigated whether there
were differences in the distribution of HLA alleles be-
tween whites and blacks in our control population and
whether our ACCESS control population was represen-
tative of the general population. The high-resolution
HLA-DRB1, HLA-DPB1, and HLA-DQB1 typing in
the control populations may represent the largest pop-
ulation to date in which high-resolution typing of HLA-
DRB1, HLA-DQB1, andHLA-DPB1was performed to
compare the HLA class II differences between blacks and
whites in the United States. Our ﬁndings (ﬁg. 1) conﬁrm
previous differences noted for HLA-DRB1*01 (Collins
et al. 2000), HLA-DRB1*03 (Tang et al. 2002), HLA-
DRB1*04 (Chen et al. 2002), HLA-DRB1*11 (Tang et
al. 2000), and HLA-DRB1*13 (Sintasath et al. 1999),
and were similar to ﬁndings for blacks in New York City
(Just et al. 1997) except for theHLA-DRB1*1503 allele.
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Table 7
Race-Speciﬁc HLA-DRB1 Allele Associations with Sarcoidosis
HLA Allele
Frequency
in Cases
(%)
Frequency
in Controls
(%) P OR
Population
Attributable
Risk
Associated with Sarcoidosis among Blacks:
DRB1*1101 31 19 .006 2.04 (1.22–3.53) 16.5
DRB1*1201 15 7 .014 2.67 (1.20–6.52) 10.5
DPB1*0101 58 44 .008 1.72 (1.14–2.62) 24.1
Associated with Controls among Blacks:
DRB1*1503 15 23 .044 .56 (.30–.99)
Associated with Sarcoidosis among Whites: 0 2 .022 .18 (.02–.83)
DRB1*1501 36 21 !.001 2.08 (1.39–3.15) 18.5
DRB1*1101 17 9 .010 2.05 (1.17–3.69) 8.6
DRB1*0402 7 3 .043 2.57 (1.02–7.28) 4.5
Associated with Controls among Whites:
DRB1*0401 12 21 .003 .44 (.25–.77)
Table 8
Forward Logistic Regression Analysis of the Association of HLA-
DRB1, HLA-DRB3, HLA-DQB1, and HLA-DPB1 Alleles and Amino
Acid Residues in Blacks and Whites with Sarcoidosis
Marker OR (95% CI) P
Associated with Sarcoidosis among Blacks:
DPB1*0101 2.20 (1.38–3.53) .001
DRB1*1201 3.23 (1.36–7.67) .008
DRB1*1101 2.24 (1.22–4.09) .009
DQB1*0502 3.19 (1.07–9.50) .037
Associated with Sarcoidosis among Whites:
DRB1*1101 3.31 (1.70–6.43) !.001
DRB1*1501 16.6 (3.24–85.0) .001
DRB1*1401 4.66 (1.85–11.8) .001
DRB1*0402 5.25 (1.90–14.5) .001
DPB1-F35 12.6 (2.03–77.5) .006
DPB1-H9 2.73 (1.26–5.93) .011
DRB1-F47 2.04 (1.15–3.64) .015
Associated with Controls among Blacks:
DRB1-Y26 .38 (.19–.77) .008
DRB1-Q10 .53 (.33–.87) .012
Associated with Controls among Whites:
DPB1-I65 .04 (.01–.31) .002
DRB1-F26 .31 (.14–.69) .004
DQB1*0602 .11 (.02–.56) .008
In addition, differences between blacks and whites were
noted in the frequencies of the HLA-DRB1*08, HLA-
DRB1*12, and HLA-DRB1*16 alleles. Differences in
the expression of DQB1 locus alleles were also noted,
especially forDQB1*0302, DQB1*0402,DQB1*0501,
DQB1*0602, andDQB1*0603. Similar differenceshave
also previously been published (Dorman and Bunker
2000).Major racial differences for theDPB1 locus alleles
were noted for DPB1*0101 and DPB1*0401 and, to
a lesser degree, for DPB1*1301, DPB1*1701, and
DPB1*1801. These ﬁndings suggest that the distribution
of HLA alleles in our control populations is similar to
the distribution of HLA alleles in the black and white
populations in the United States and illustrate the need
to analyze black and white populations separately and
with their own matched control groups. It has been
known for years that U.S. blacks, on average, have 30%
white admixture (Steinberg 1969). Although this could
be an important possible weakness of this study, it is
important to realize that this was a matched case-control
study and was matched on self-designated race.
HLA-DRB1*1101 appears to be the most important
susceptibility factor among the HLA class II alleles for
sarcoidosis as this allele was signiﬁcantly associated with
sarcoidosis in both blacks and whites. Since the distri-
bution of alleles in our black and white control popu-
lations appears to be similar to the distribution of alleles
in the black and white populations in the United States,
we were able to calculate the population attributable risk
for sarcoidosis due to this allele. The population attrib-
utable risk was 16.5% for blacks and 8.5% for whites.
Similarly, in a study of Japanese patients (Ishihara et
al. 1994) with sarcoidosis predominantly affecting the
eye (58 of 63 subjects had eye involvement), HLA-
DRB1*1101 was signiﬁcantly increased compared with
controls. This ﬁnding is of added interest because of the
recent observation of a decreased prevalence of HLA-
DRB1*11 alleles in patients with hepatitis C (Yenigun
and Durupinar 2002), a disease that worsens with cor-
ticosteroid treatment of sarcoidosis.
In the evaluation of the study sample, HLA-DPB1
alleles did not appear to be associated with sarcoidosis.
However, in blacks, a signiﬁcant association was ob-
served for HLA-DPB1 that appeared to be accounted
for entirely by HLA-DPB1*0101. Because of the high
prevalence of this allele in the black control population,
this allele had a population attributable risk of 24.1%.
Importantly, only one allele, HLA-DRB1*1501, ap-
peared to be differentially associated with sarcoidosis
in blacks and whites (associated with controls in blacks
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Table 9
Clinical Involvement in Sarcoidosis Associated with HLA Class II Alleles
ALLELE AND
SARCOIDOSIS PHENOTYPEa
VALUE IN
Entire Population Blacks Whites
OR (95% CI) P OR (95% CI) P OR (95% CI) P
DRB1*1101:
Calcium metabolism 1.66 (.66–4.19) .28 .55 (.06–5.00) .59 3.28 (1.13–9.54) .02
Extra-thoracic lymph nodes 1.75 (1.00–3.05) .05 1.59 (.76–3.33) .21 1.53 (.61–3.80) .36
DRB1*1201:
Ear, nose and throat 4.03 (1.23–13.1) .01 4.62 (.98–21.8) .04 3.47 (.31–30.8) .24
Neurological .97 (.21–4.27) .96 .00b .15 5.13 (.98–26.8) .03
DRB3:
Bone marrow 2.33 (.81–6.71) .11 6.71 (2.09–21.5) .004 .00b .50
DRB1*0401:
Eye 3.49 (1.62–7.54) .0008 4.73 (.64–34.8) .10 5.77 (2.27–14.6) .0001
Neurological 3.37 (1.18–9.59) .02 5.97 (.57–62.6) .09 3.23 (.95–11.0) .05
Parotid and salivary glands 2.61 (.84–8.10) .09 78.0 (7.18–848) !.001 .55 (.07–4.38) .57
DRB1*0402:
Erythema nodosum 3.05 (.96–9.73) .048 …c 3.92 (1.16–13.2) .02
DRB1*1503:
Bone marrow 6.06 (1.80–20.3) .001 2.46 (.72–8.46) .14 …c
Extra-thoracic lymph nodes 3.20 (1.43–7.17) .003 2.56 (1.07–6.08) .03 …c
Neurological 3.10 (.99–9.69) .04 3.59 (.98–13.2) .04 …c
DRB5:
Neurological 1.28 (.55–2.97) .56 3.91 (1.12–13.6) .02 .62 (.19–2.02) .42
Parotid and salivary glands 2.36 (1.03–5.38) .04 1.88 (.46–7.64) .37 3.01 (.98–9.26) .04
DPB1*0101:
Calcium metabolism 1.22 (.50–2.98) .66 .47 (.08–2.90) .41 4.28 (1.45–12.6) .005
Eye 1.75 (1.01–3.04) .05 1.49 (.69–3.19) .31 .54 (.12–2.41) .42
a Speciﬁc deﬁnitions are given by Judson et al. (1999).
b The CI of the OR could not be determined, since no cases of neurological involvement occurred in blacks withHLA-
DRB1*1201.
c No alleles were detected in the subpopulation.
[OR 0.36] and with sarcoidosis in whites [OR 2.08;
for interaction]). However, this study was un-Pp .003
derpowered to detect signiﬁcant differential associations
in alleles of low frequency. Nevertheless, the majority
of HLA class II alleles that are associated with sarcoid-
osis may be similar in both blacks and whites, and the
increased frequency of sarcoidosis in blacks could be
due to the different distribution ofHLA alleles in blacks
compared to that in whites. Similarly, Grunewald and
Eklund (Grunewald and Eklund 2001) recently reported
a case of sarcoidosis in an African that had an HLA
type (DR 17) that has been associated with a speciﬁc
immunological proﬁle (i.e., increased lung T cells that
express the AV2S3 T cell receptor) and clinical presen-
tation, Lofgren syndrome, that is frequently seen in
Scandinavians and is unusual in Africans.
Because linkage disequilibrium complicates the inter-
pretation of the HLA associations, controversy exists
whether several HLA factors or a single HLA allele or
genotype can explain sarcoidosis associations within the
MHC region. For instance, in white populations, the
DQB1 and DRB1 loci are in very tight linkage dis-
equilibrium, with the allele at one locus generally pre-
dicting the allele at the other locus (Begovich et al.
1992). The degree of linkage disequilibrium between
the DQB1 and DRB1 loci in blacks may not be as
strong (Zachary et al. 2001). This might explain the
recent ﬁndings suggesting that the DQB1 locus is the
primary HLA class II susceptibility gene in blacks (Ry-
bicki et al. 2003). Although we chose to focus on the
DRB1 and DPB1 sarcoidosis associations that were
most prominent in our data, on the basis of our statis-
tical approach (logistic regressions), we did observe an
association of HLA-DQB1*0502 in blacks that is con-
sistent with a role for HLA-DQB1 in susceptibility to
sarcoidosis.
Because of linkage disequilibrium in the HLA region,
speciﬁc HLA-A, HLA-B, and HLA-DR haplotypes have
been identiﬁed (Schipper et al. 1997) that can extend
from theHLA class II region through the class III region
and into the class I region. Whether speciﬁc genes or
cassettes of genes inherited as a haplotype account for
the susceptibility to sarcoidosis is not known. Associ-
ations with sarcoidosis have been observed with poly-
morphisms of the class II gene DMB (Ishihara et al.
1996), the class III gene TNF-a (Grutters et al. 2002),
Figure 1 HLA class II alleles differentially expressed in blacks and whites. The alleles that were signiﬁcantly different (x2 ) areP ! .05
illustrated. The proportion of the population expressing a speciﬁc allele is shown on the abscissa (white bars for whites, black bars for blacks).
A, HLA-DRB1 alleles. B, HLA-DQB1 alleles. C, HLA-DPB1 alleles.
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and, in some studies, with speciﬁc phenotypes of sar-
coidosis with TNF-a polymorphisms (Swider et al.
1999; Pandey and Frederick 2002) and with the sero-
logically deﬁned class I antigen B8 (Lenhart et al. 1990;
Dubaniewicz and Szczerkowska 1999). Until there is
identiﬁcation of the genetic polymorphisms that com-
prise speciﬁc conserved haplotypes in the HLA region,
the association of these haplotypes with sarcoidosis and
the speciﬁc genes accounting for the susceptibility to
sarcoidosis may be uncertain.
Peptides bind to HLA class II molecules via amino
acid residues that project down into the HLA class II
cleft into speciﬁcity pockets (Stern et al. 1994). The
speciﬁc amino acids of theHLA class II speciﬁcity pock-
ets have been shown to determine peptide binding (An-
droulakis et al. 1997; Chelvanayagam 1997). In addi-
tion, the presence or absence of speciﬁc amino acid
residues has been associated with insulin-dependent di-
abetes, rheumatoid arthritis (Dorman and Bunker 2000;
Zanelli et al. 2000), and chronic beryllium disease (a
granulomatous disease similar to sarcoidosis) (Richeldi
et al. 1993; Wang et al. 1999; Rossman et al. 2002b).
We were also able to show here that speciﬁc HLA class
II amino acid residues deﬁned susceptibility to sarcoid-
osis. We were surprised to ﬁnd that speciﬁc alleles ap-
peared to be more important than amino acid residues
for deﬁning susceptibility to sarcoidosis. Nevertheless,
certain amino acid residues appear to be important for
the susceptibility to sarcoidosis.HLA-DRB1-F47, which
was the amino acid residue most associated, by uni-
variate analysis, with sarcoidosis (table 5), was present
on the three alleles most associated with sarcoidosis—
HLA-DRB1*1101, HLA-DRB1*1201, and HLA-
DRB1*1501—but was also present on one of the al-
leles associated with the control population, HLA-
DRB1*1503. Thus, in the logistic regression (table 6),
this amino acid residue did not appear to independently
add to the risk of sarcoidosis. However, in whites who
did not have a HLA-DRB1*1503 allele, HLA-DRB1-
F47 appeared to independently contribute to the risk of
sarcoidosis (table 8) and may be the most important
amino acid residue associated with peptide binding in
sarcoidosis. Amino acid residues at position 47 would
affect pocket 7 (Androulakis et al. 1997; Chelvanaya-
gam 1997), and mutations of the amino acid residues
of pocket 7 peptides have been shown to affect T cell
recognition (Evavold et al. 1993; Spain et al. 1994; Hsu
et al. 1995).
Foley et al., in a study of European patients with
sarcoidosis that used low-resolution HLA typing, ob-
served that HLA-DRB1-V11 and –L11 amino acid resi-
dues were associated with protection from sarcoidosis
(Foley et al. 2001). In our study, HLA-DRB1-V11 was
associated with the control population, “protection,”
and HLA-DRB1-S11 was associated with sarcoidosis
(table 5). However, in our study, the most signiﬁcant
association with protection was with HLA-DRB1-H13.
This amino acid is always associated with HLA-DRB1-
V11 with the HLA-DRB1*04 alleles but is not present
on the HLA-DRB1*1001 allele, which does contain -
V11. Thus, we feel that it is more likely that the asso-
ciation with HLA-DRB1-H13 explains their association
with position 11 and suggests that pocket 4, which is
associated with HLA-DRB1-H13, may be important in
protection from sarcoidosis, rather than pocket 6, which
is associated with position 11. This may have important
implications for identifying immunogenic peptides that
bind class II molecules in sarcoidosis.
Prior studies have demonstrated a strong association
between HLA-DPB1-E69 and chronic beryllium disease
(Richeldi et al. 1993; Wang et al. 1999; Rossman et al.
2002b). Because of the similarity of chronic beryllium
disease to sarcoidosis, prior studies have looked for an
association of sarcoidosis with HLA-DPB1-E69 (Mali-
arik et al. 1998; Foley et al. 1999). We also did not ﬁnd
any association of HLA-DPB1-E69 with sarcoidosis.
However, we did ﬁnd an association with the amino
acid residue DPB1-V76 in the entire study sample. This
amino acid residue is present in HLA-DPB1*0101, the
frequency of which was signiﬁcantly increased in blacks
with sarcoidosis. In the European population that was
typed for HLA-DPB1, all alleles containing DPB1-V76
(DPB1*0101, DPB1*0301,DPB1*0801,DPB1*1001,
and DPB1*1401) except one (DPB1*0901) were more
frequent in patients with sarcoidosis than in controls
suggesting that DPB1-V76 might be an importantmarker
for sarcoidosis. In a black population (Maliarik et al.
1998), DPB1-F35 was increased, and we also noted an
increase in this amino acid residue in our white popu-
lation. These ﬁndings suggest that the HLA-DPB1 lo-
cus alleles may also be markers for susceptibility to
sarcoidosis.
In addition to being susceptibility markers for sar-
coidosis, HLA class II genes may also be susceptibility
markers for a particular form or presentation of sar-
coidosis. Such ﬁndings have been reported for rheu-
matoid arthritis (Hellier et al. 2001; Vos et al. 2001),
tuberculosis (Ravikumar et al. 1999; Dubaniewicz et al.
2000), and chronic beryllium disease (Rossman et al.
2002b). In sarcoidosis, Swedish (Berlin et al. 1997),
Danish (Bogunia-Kubik et al. 2001), and German and
Polish (Swider et al. 1999) patients who express
DRB1*03 are more likely to have Lofgren syndrome
and a nonchronic form of the disease, whereas cardiac
sarcoidosis has been associated with Japanese patients
with HLA-DQB1*0601 (Naruse et al. 2000). We also
noted that the clinical presentation appeared to be as-
sociated with speciﬁcHLA class II alleles (table 6). Find-
ing phenotypes of sarcoidosis associated withHLA class
II alleles has several important implications. First, since
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sarcoidosis is a polygenic disorder, other genes must be
associated with sarcoidosis. Thus, speciﬁc HLA class II
alleles may determine the phenotype of sarcoidosis and
not the predisposition to develop a sarcoidlike reaction.
Candidate genes have been identiﬁed that could be
linked to the HLA class II region as a speciﬁc haplotype
(Ishihara et al. 1996; Rybicki et al. 1999; Pandey and
Frederick 2002; Zorzetto et al. 2002) or be present on
other chromosomes (Arbustini et al. 1996; Rybicki et
al. 1999; Planck et al. 2002; Zorzetto et al. 2002). The
report of other areas of the genome linked to sarcoidosis
supports both possibilities (Schurmann et al. 2001). Sec-
ond, because HLA class II alleles may select speciﬁc
environmental agents, the phenotype of the disease may
relate to the localization of the selected environmental
agent. Preliminary studies suggest that environmental-
HLA class II associations do exist in sarcoidosis (Ross-
man et al. 2002a), and HLA class II alleles may be a
signiﬁcant tool to determine the environmental causes/
triggers of sarcoidosis.
Although it is attractive to speculate that speciﬁc en-
vironmental or infectious agents will be associated with
one or more alleles or amino acid variants in the poly-
morphic positions of theHLA; unfortunately, this is not
necessarily true. For small metals, such as beryllium, it
appears to be true (Richeldi et al. 1993). However, for
responses to bacteria or mycobacteria, it is not neces-
sarily true, as there may be multiple immunogenic pep-
tides and thus a predominant HLA allele or amino acid
residue is not always found (Vejbaesya et al. 2002).
Thus, our ﬁndings could support several theories about
the cause of sarcoidosis. First, that it might be caused
by multiple small molecules present in the environment
like beryllium. Second, it might be caused by an organ-
ism like tuberculosis. Third, it might be caused by a
combination of the two.
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